Compound class:
Peptide
Comment: This is a small peptide that mimics the glycosaminoglycan (GAG) binding domain found in the C-terminal α helix of the CXCL8 cytokine [2]. It competes with CXCL8 for binding to GAGs, and by interfering in this interaction, reduces CXCL8-mediated inflammatory responses (leukocyte activation and extravasation to inflammatory sites).
The archetypal GAG-binding motif on CXC chemokines takes the form XBBBXXBX (where B = a basic amino acid and X = any nonbasic amino acid) [3]. The reference article also describes small peptides that interfere with CCL5 and CXCL12γ GAG binding [2]. Chemokine interactions with GAGs localise the chemokines around cell surfaces and the extracellular matrix. This provides a guidance mechanism for leukocyte migration [4]. Disrupting this guidance mechanism is predicted to produce anti-inflammatory effects, by reducing the ability of pro-inflammatory cells to migrate to sites of inflammation in response to cytokine signals. |
|
Immunopharmacology Comments |
pCXCL8-1aa reduces disease severity and serum levels of proinflammatory TNFα in a murine antigen-induced arthritis model, an effect that is mediated by reduced leukocyte activation and infiltration at arthritic sites. Disruption of the cytokine-GAG-cytokine receptor axis is considered as a novel mechanism to be expolited for the development of new classes of anti-inflammatory agents [1]. |